Clinical Trials Snapshot

Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)

Phase 1, interventional, open-label study of GAP T cells for patients with GPC3-positive liver cancers.

Phase 1, interventional, open-label study of GAP T cells for patients with GPC3-positive liver cancers.